| General Information | |
|---|---|
| ZINC ID | ZINC000042875569 |
| Molecular Weight (Da) | 566 |
| SMILES | N#Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(I)cc1 |
| Molecular Formula | C22Cl2I1N5O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 131.256 |
| HBA | 4 |
| HBD | 1 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 31 |
| LogP | 5.988 |
| Activity (Ki) in nM | 33.1131 |
| Polar Surface Area (PSA) | 73.95 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.982 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.23 |
| Ilogp | 4.37 |
| Xlogp3 | 5.87 |
| Wlogp | 5.07 |
| Mlogp | 4.4 |
| Silicos-it log p | 4.91 |
| Consensus log p | 4.92 |
| Esol log s | -7.12 |
| Esol solubility (mg/ml) | 0.0000425 |
| Esol solubility (mol/l) | 7.51E-08 |
| Esol class | Poorly sol |
| Ali log s | -7.2 |
| Ali solubility (mg/ml) | 0.0000361 |
| Ali solubility (mol/l) | 6.38E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.18 |
| Silicos-it solubility (mg/ml) | 0.00000375 |
| Silicos-it solubility (mol/l) | 6.62E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.59 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 1 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.46 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.391 |
| Logd | 3.992 |
| Logp | 5.225 |
| F (20%) | 0.001 |
| F (30%) | 0.001 |
| Mdck | - |
| Ppb | 99.90% |
| Vdss | 0.279 |
| Fu | 0.84% |
| Cyp1a2-inh | 0.17 |
| Cyp1a2-sub | 0.582 |
| Cyp2c19-inh | 0.859 |
| Cyp2c19-sub | 0.429 |
| Cl | 6.9 |
| T12 | 0.026 |
| H-ht | 0.914 |
| Dili | 0.977 |
| Roa | 0.328 |
| Fdamdd | 0.834 |
| Skinsen | 0.166 |
| Ec | 0.003 |
| Ei | 0.011 |
| Respiratory | 0.475 |
| Bcf | 1.973 |
| Igc50 | 4.972 |
| Lc50 | 6.282 |
| Lc50dm | 6.224 |
| Nr-ar | 0.01 |
| Nr-ar-lbd | 0.271 |
| Nr-ahr | 0.893 |
| Nr-aromatase | 0.912 |
| Nr-er | 0.541 |
| Nr-er-lbd | 0.201 |
| Nr-ppar-gamma | 0.956 |
| Sr-are | 0.891 |
| Sr-atad5 | 0.064 |
| Sr-hse | 0.843 |
| Sr-mmp | 0.946 |
| Sr-p53 | 0.974 |
| Vol | 445.314 |
| Dense | 1.269 |
| Flex | 0.2 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 2 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.427 |
| Synth | 2.716 |
| Fsp3 | 0.227 |
| Mce-18 | 54.519 |
| Natural product-likeness | -1.805 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |